These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 8263128

  • 1. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
    Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV.
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1458-64. PubMed ID: 8263128
    [Abstract] [Full Text] [Related]

  • 2. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
    Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD, Schally AV.
    Cancer Res; 1993 Nov 15; 53(22):5439-46. PubMed ID: 8221683
    [Abstract] [Full Text] [Related]

  • 3. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C, Völker P, Schulz KD, Emons G.
    Gynecol Oncol; 2000 Aug 15; 78(2):194-202. PubMed ID: 10926802
    [Abstract] [Full Text] [Related]

  • 4. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
    Gründker C, Völker P, Emons G.
    Endocrinology; 2001 Jun 15; 142(6):2369-80. PubMed ID: 11356684
    [Abstract] [Full Text] [Related]

  • 5. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
    Borri P, Coronnello M, Noci I, Pesciullesi A, Peri A, Caligiani R, Maggi M, Torricelli F, Scarselli G, Chieffi O, Mazzei T, Mini E.
    Gynecol Oncol; 1998 Dec 15; 71(3):396-403. PubMed ID: 9887238
    [Abstract] [Full Text] [Related]

  • 6. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Grundker C, Schally AV, Emons G.
    Int J Oncol; 2000 Nov 15; 17(5):1063-9. PubMed ID: 11029513
    [Abstract] [Full Text] [Related]

  • 7. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR, Gründker C, Böttcher B, Emons G.
    Anticancer Res; 2004 Nov 15; 24(3a):1727-32. PubMed ID: 15274347
    [Abstract] [Full Text] [Related]

  • 8. Expression of luteinizing hormone releasing hormone and its mRNA in human endometrial cancer cell lines.
    Irmer G, Bürger C, Ortmann O, Schulz KD, Emons G.
    J Clin Endocrinol Metab; 1994 Sep 15; 79(3):916-9. PubMed ID: 8077383
    [Abstract] [Full Text] [Related]

  • 9. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
    Srkalovic G, Bokser L, Radulovic S, Korkut E, Schally AV.
    Endocrinology; 1990 Dec 15; 127(6):3052-60. PubMed ID: 2174343
    [Abstract] [Full Text] [Related]

  • 10. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
    Zhao LJ, Wei LH, Li XP, Wang JL.
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan 15; 44(1):45-9. PubMed ID: 19563062
    [Abstract] [Full Text] [Related]

  • 11. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR, Gründker C, Bongertz T, Schlott T, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2004 Oct 15; 191(4):1164-72. PubMed ID: 15507937
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T, Pinski J, Radulovic S, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Mar 01; 91(5):1701-5. PubMed ID: 8127868
    [Abstract] [Full Text] [Related]

  • 13. Phosphatase and tensin homolog gene inhibits the effect induced by gonadotropin-releasing hormone subtypes in human endometrial carcinoma cells.
    Zhao LJ, Liu N, Li XP, Wang JL, Wei LH.
    Chin Med J (Engl); 2010 May 05; 123(9):1170-5. PubMed ID: 20529558
    [Abstract] [Full Text] [Related]

  • 14. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I, Vincze B, Kálnay A, Turi G, Mezõ I, Teplán I, Seprõdi J, Pató J, Móra M.
    Cancer Detect Prev; 1996 May 05; 20(2):146-52. PubMed ID: 8706040
    [Abstract] [Full Text] [Related]

  • 15. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues.
    Völker P, Gründker C, Schmidt O, Schulz KD, Emons G.
    Am J Obstet Gynecol; 2002 Feb 05; 186(2):171-9. PubMed ID: 11854630
    [Abstract] [Full Text] [Related]

  • 16. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
    Milovanovic SR, Monje E, Szepeshazi K, Radulovic S, Schally A.
    J Cancer Res Clin Oncol; 1993 Feb 05; 119(5):273-8. PubMed ID: 8382705
    [Abstract] [Full Text] [Related]

  • 17. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
    Srkalovic G, Wittliff JL, Schally AV.
    Cancer Res; 1990 Mar 15; 50(6):1841-6. PubMed ID: 2155060
    [Abstract] [Full Text] [Related]

  • 18. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
    Gründker C, Günthert AR, Millar RP, Emons G.
    J Clin Endocrinol Metab; 2002 Mar 15; 87(3):1427-30. PubMed ID: 11889221
    [Abstract] [Full Text] [Related]

  • 19. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G.
    Fertil Steril; 2005 Apr 15; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [Abstract] [Full Text] [Related]

  • 20. Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
    Gründker C, Schlotawa L, Viereck V, Emons G.
    Eur J Endocrinol; 2001 Nov 15; 145(5):651-8. PubMed ID: 11720885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.